Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Olaparib Tablets in Cancer Patients
NCT05860530Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of olaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Plasma Drug Concentration at Steady State at Day 7 and Area Under the Concentration-time Curve Over the Dosing Interval. Started May 2021; status: completed.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05860530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860530.